A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-16

Study Completion Date

2021-03-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is randomized, single-blind, placebo-controlled Phase 1 study aimed to assess the safety and efficacy, pharmacokinetics and pharmacodynamics of multiple doses of oral AZD4831 in healthy Japanese and Chinese volunteers

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.

NCT06381466

Dilated Cardiomyopathy

TERMINATED PHASE1

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants

NCT07290283

Healthy Participants

RECRUITING PHASE1

Assessment of the Safety and Pharmacokinetics of Single and Multiple Oral Doses of AZD4316 in Healthy Subjects

NCT01247103

Healthy Volunteers

WITHDRAWN PHASE1

A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers

NCT06951880

Healthy Participants

NOT_YET_RECRUITING PHASE1

Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 in Healthy Volunteers

NCT00940212

Healthy Volunteers

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase I, randomized, single-blind, placebo-controlled, multiple-ascending dose (MAD), sequential-group study in healthy Japanese (Part 1, Cohorts 1, 2, and 3) and Chinese (Part 2, Cohort 4) male subjects, conducted at a single study center. Four cohorts are planned, but one additional cohort may be enrolled based on a Safety Review Committee (SRC) decision.

The 4 multiple dose levels are planned as follows:

* Cohort 1: Dose 1
* Cohort 2: Dose 2
* Cohort 3: Dose 3
* Cohort 4: Dose 2

A randomization ratio of 3:1 (AZD4831 versus placebo) will be used.

For each cohort the study will comprise:

* Screening Period of a maximum of 28 days.
* A Treatment Period during which subjects are resident in the study center from the day before first dosing with the Investigational Medicinal Product (Day -1) until at least 48 hours after last dosing on Day 10; subjects will be discharged on Day 12.
* Three Follow-up Visits on Day 14, Day 16 (±1 day), and Day 20 (±1 day).
* A Final Follow-up Visit on Day 24 (±2 days).

Each subject will be involved in the study for 8 to 9 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure With Preserved Ejection Fraction (HFpEF)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

This study will be a randomized, single-blind, placebo-controlled, MAD sequential-group study in healthy Japanese (Part 1, Cohorts 1, 2, and 3) and Chinese (Part 2, Cohort 4) male subjects, conducted at a single study center. Up to 40 healthy male subjects aged 18 to 50 years (inclusive) are planned to be investigated in 4 cohorts, but up to 5 cohorts may be included if the SRC considers it necessary to repeat a dose level or if additional dose levels are required.

Up to 8 subjects will participate in each cohort. Within each cohort 6 subjects will be randomly assigned to receive AZD4831 and 2 subjects to receive placebo. AZD4831 or placebo will be administered once daily for a period of 10 days. It is anticipated this will be sufficient to achieve and maintain steady state pharmacokinetic (PK) profiles for several days, permitting evaluation of the safety and tolerability of multiple dose. The subjects will stay at the study center during the whole dosing period and until 48 hours.

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

This study is single-blind with regards to treatment (AZD4831 or placebo) at each dose level. AZD4831 and placebo will be matched for appearance and amount. Subjects randomized to placebo will receive the same volume of oral suspension as subjects on active drug.

* History of any clinically important disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
* History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs.
* Presence of infection(s) (particularly fungal infection), as judged by the Investigator.
* History of, or current thyroid disease.
* Any ongoing skin disorder, history of or ongoing clinically significant allergy/hypersensitivity.
* Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of investigational medicinal product (IMP).
* Any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results, as judged by the Investigator at Screening and/or Day -1.

1. Alanine transaminase (ALT) not within normal range
2. Aspartate aminotransferase (AST) not within normal range
3. Creatinine not within normal range
4. White blood cell (WBC) count not within normal range
5. Hemoglobin not within normal range;
6. Estimated Glomerular Filtration Rate (eGFR) not within normal range.
* Any positive result at Screening for serum hepatitis B surface antigen, hepatitis C antibody and human immunodeficiency virus (HIV) type 1 and 2.
* Abnormal vital signs, after 10 minutes supine rest, at Screening and/or Day -1, defined as any of the following:

1. SBP \< 90 mmHg or ≥ 140 mmHg.
2. DBP \< 50 mmHg or ≥ 90 mmHg.
3. Pulse \< 45 or \> 85 bpm.
* Any clinically significant abnormalities in rhythm, conduction or morphology of the resting electrocardiogram (ECG) and/or any clinically significant abnormalities in the 12-lead ECG, as judged by the Investigator that may interfere with the interpretation of QTc interval changes, including abnormal ST-T-wave morphology, particularly in the protocol defined primary lead or left ventricular hypertrophy at Screening and/or Day -1.
* Prolonged QTcF \> 450 ms or shortened QTcF \< 340 ms or family history of long QT syndrome at Screening and/or Day -1.
* PR(PQ) interval shortening \< 120 ms (PR \> 110 ms but \< 120 ms is acceptable if there is no evidence of ventricular pre-excitation) at Screening and/or Day -1.
* PR(PQ) interval prolongation (\> 240 ms) intermittent second (Wenckebach block while asleep is not exclusive) or third-degree atrioventricular (AV)-block, or AV dissociation at Screening and/or Day -1.
* Persistent or intermittent complete bundle branch block, incomplete bundle branch block, or interventricular conduction delay with QRS \> 110 ms. Subjects with QRS \> 110 ms but \< 115 ms are acceptable if there is no evidence of, for example, ventricular hypertrophy or pre-excitation at Screening and/or Day -1.
* Electrocardiogram findings suggesting a metabolic or other non-cardiac condition that may confound interpretation of serial changes (such as hypokalemia) at Screening and/or Day -1.
* Known or suspected history of drug abuse as judged by the Investigator.
* Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within 3 months of Screening.
* History of alcohol abuse or excessive intake of alcohol as judged by the Investigator.
* Positive screen for drugs of abuse, cotinine (nicotine) or alcohol at Screening and/or Day -1.
* History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the Investigator or history of hypersensitivity to drugs with myeloperoxidase (MPO) inhibitors and anti-thyroid drugs with similar theorem motifs as AZD4831.
* Excessive intake of caffeine-containing drinks or food (e.g., coffee, tea, chocolate,) as judged by the Investigator.
* Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP.
* Use of any prescribed or nonprescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, mega-dose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of IMP or longer if the medication has a long half-life.
* Plasma donation within 1 month of Screening or any blood donation/blood loss \> 500 mL during the 3 months before Screening.
* Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 1 month of first administration of IMP in this study (period of exclusion begins 1 month after the final dose of the previous chemical entity or last visit in the previous study, whichever is longest),

1. if the previous chemical entity has a half-life that would not indicate complete clearance at the time of screening to this study,
2. if the previous chemical entity has significant drug-drug interactions or enzyme inductions that could potentially have an impact on the PK of this study's IMP, even if the previous chemical entity is cleared at the time of screening to this study,
3. and if the subject has not completed all follow-up activity in the previous study, including last study visit, unresolved AEs, and abnormal laboratory values.
* Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
* Involvement of any Astra Zeneca, Parexel or study site employee or their close relatives.
* Judgement by the Investigator that the subject should not participate in the study if they have any ongoing or recent (i.e., during the Screening Period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements.
* Subjects who are vegans or have medical dietary restrictions, or any other dietary restrictions.
* Subjects who cannot communicate reliably with the Investigator.
* Previous bone marrow transplant.
* Non leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes